UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000022649 |
|---|---|
| Receipt number | R000026113 |
| Scientific Title | The safety evaluation of excessive intake of Saccharomyces cerevisiae SM-10 in healthy adults |
| Date of disclosure of the study information | 2016/06/07 |
| Last modified on | 2016/11/08 15:46:57 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
The safety evaluation of excessive intake of Saccharomyces cerevisiae SM-10 in healthy adults
Acronym
Safety evaluation of excessive intake of Saccharomyces cerevisiae SM-10
Scientific Title
The safety evaluation of excessive intake of Saccharomyces cerevisiae SM-10 in healthy adults
Scientific Title:Acronym
Safety evaluation of excessive intake of Saccharomyces cerevisiae SM-10
Region
| Japan |
Condition
Condition
Healthy adult
Classification by specialty
| Adult |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To evaluate the safety of excessive intake of SM-10 supplements for 4 weeks.
Basic objectives2
Safety
Basic objectives -Others
Trial characteristics_1
Confirmatory
Trial characteristics_2
Pragmatic
Developmental phase
Assessment
Primary outcomes
Hematologic test
Blood biochemistry test
Urine test
Blood pressure/pulsation
Weight/body mass index
Medical Interview
Adverse event
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Prevention
Type of intervention
| Food |
Interventions/Control_1
SM-10 supplements are ingested for 4 consecutive weeks at 3,000 mg.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 64 | years-old | >= |
Gender
Female
Key inclusion criteria
Healthy males and females at the ages of 20 to 64
Key exclusion criteria
1. Subjects who routinely use health food containing S-adenosyl methionine
2. Subjects having a current or past history of serious diseases such as diabetes, hepatic or renal disorder, or cardiovascular disease
3. Subjects having possibilities for emerging allergy related to the study
4. Subjects having possibilities for emerging allergy related to the study
5. Subjects who are judged as unsuitable for the study based on the results of clinical and physical examination on preliminary examination
6. Subjects who have participated in other clinical studies within the last one month prior to the current study or are planned to participate in other studies after obtaining informed consent for the current study
7. Subjects who intend to become pregnant or lactating
8. Subjects who are judged as unsuitable for the study based on the results of lifestyle questionnaire
9. Subjects who are judged as unsuitable for this study by physician
Target sample size
10
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | hiroyuki kimura |
Organization
Horus Co., Ltd.
Division name
Academic Planning Department
Zip code
Address
3-3-5 Nakano Nakano-ku Tokyo
TEL
03-5328-9331
kimura.hiroyuki@horus-jnl.co.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | hiroko onoda, tomohiro utsue, sayuri fujita |
Organization
Horus Co., Ltd.
Division name
Academic Planning Department
Zip code
Address
3-3-5 Nakano Nakano-ku Tokyo
TEL
03-5328-9331
Homepage URL
http://horus-jnl.com/
gakujutu.mail@horus-jnl.co.jp
Sponsor or person
Institute
TTC CO., LTD.
Institute
Department
Personal name
Funding Source
Organization
Horus Co., Ltd.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2016 | Year | 06 | Month | 07 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2016 | Year | 05 | Month | 26 | Day |
Date of IRB
Anticipated trial start date
| 2016 | Year | 06 | Month | 08 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2016 | Year | 06 | Month | 07 | Day |
Last modified on
| 2016 | Year | 11 | Month | 08 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026113
